APO Research
Talk to an analyst

APO RESEARCH · REPORT

Short-acting Insulin

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Short-acting Insulin Industry Growth and Trends Forecast to 2032

28 December 2025101 pages

Choose your research edition.

Industry ResearchShort-acting Insulin Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Short-acting Insulin Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Short-acting Insulin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Short-acting Insulin Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Short-acting Insulin Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Short-acting Insulin market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Short-acting Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Short-acting Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Short-acting Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Short-acting Insulin include Zhuhai United Pharmaceutical, Wanbang Biopharmaceuticals, Sinovac Biotech, HTBT, Tonghua Dongbao Pharmaceutical, Wockhardt, Sanofi, Pfizer and Novo Nordisk, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Short-acting Insulin market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Short-acting Insulin market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Short-acting Insulin market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Short-acting Insulin.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Short-acting Insulin market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Short-acting Insulin Market by Company

Zhuhai United Pharmaceutical

Wanbang Biopharmaceuticals

Sinovac Biotech

HTBT

Tonghua Dongbao Pharmaceutical

Wockhardt

Sanofi

Pfizer

Novo Nordisk

Eli Lilly

Biocon Biologics

Bayer

BASF

Abbott Laboratories

Short-acting Insulin Segment by Type

Regular Insulin

Biosynthetic Human Insulin

Recombinant Human Insulin

Other

Short-acting Insulin Segment by Application

Type 2 Diabetes

Type 1 Diabetes

Gestational Diabetes

Complications of Diabetes

Other

Short-acting Insulin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Short-acting Insulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Short-acting Insulin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Short-acting Insulin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Short-acting Insulin manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Short-acting Insulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Regular Insulin Table 2. Major Company of Biosynthetic Human Insulin Table 3. Major Company of Recombinant Human Insulin Table 4. Major Company of Other Table 5. Global Short-acting Insulin Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Short-acting Insulin Sales by Type (2021-2026) & (K Units) Table 7. Global Short-acting Insulin Sales Market Share in Volume by Type (2021-2026) Table 8. Global Short-acting Insulin Sales by Type (2021-2026) & (US$ Million) Table 9. Global Short-acting Insulin Sales Market Share in Value by Type (2021-2026) Table 10. Global Short-acting Insulin Price by Type (2021-2026) & (US$/Unit) Table 11. Global Short-acting Insulin Sales by Type (2027-2032) & (K Units) Table 12. Global Short-acting Insulin Sales Market Share in Volume by Type (2027-2032) Table 13. Global Short-acting Insulin Sales by Type (2027-2032) & (US$ Million) Table 14. Global Short-acting Insulin Sales Market Share in Value by Type (2027-2032) Table 15. Global Short-acting Insulin Price by Type (2027-2032) & (US$/Unit) Table 16. North America Short-acting Insulin Sales by Type (2021-2026) & (K Units) Table 17. North America Short-acting Insulin Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Short-acting Insulin Sales by Type (2021-2026) & (K Units) Table 19. Europe Short-acting Insulin Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Short-acting Insulin Sales by Type (2021-2026) & (K Units) Table 21. Asia-Pacific Short-acting Insulin Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Short-acting Insulin Sales by Type (2021-2026) & (K Units) Table 23. Latin America Short-acting Insulin Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Short-acting Insulin Sales by Type (2021-2026) & (K Units) Table 25. Middle East and Africa Short-acting Insulin Sales by Type (2021-2026) & (US$ Million) Table 26. Short-acting Insulin Industry Trends Table 27. Short-acting Insulin Industry Drivers Table 28. Short-acting Insulin Industry Opportunities and Challenges Table 29. Short-acting Insulin Industry Restraints Table 30. Global Short-acting Insulin Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Short-acting Insulin Revenue Market Share by Company (2021-2026) Table 32. Global Short-acting Insulin Sales by Company (2021-2026) & (K Units) Table 33. Global Short-acting Insulin Sales Share by Company (2021-2026) Table 34. Global Short-acting Insulin Market Price by Company (2021-2026) & (US$/Unit) Table 35. Global Short-acting Insulin Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Short-acting Insulin Major Company Production Sites and Headquarters Table 37. Global Short-acting Insulin Company, Product Type & Application Table 38. Global Short-acting Insulin Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Short-acting Insulin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Short-acting Insulin Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Short-acting Insulin Sales by Region (2021-2026) & (K Units) Table 43. Global Short-acting Insulin Sales Market Share in Volume by Region (2021-2026) Table 44. Global Short-acting Insulin Sales by Region (2021-2026) & (US$ Million) Table 45. Global Short-acting Insulin Sales Market Share in Value by Region (2021-2026) Table 46. Global Short-acting Insulin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 47. Global Short-acting Insulin Sales by Region (2027-2032) & (K Units) Table 48. Global Short-acting Insulin Sales Market Share in Volume by Region (2027-2032) Table 49. Global Short-acting Insulin Sales by Region (2027-2032) & (US$ Million) Table 50. Global Short-acting Insulin Sales Market Share in Value by Region (2027-2032) Table 51. Global Short-acting Insulin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 52. Global Short-acting Insulin Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Short-acting Insulin Sales by Application (2021-2026) & (K Units) Table 54. Global Short-acting Insulin Sales Market Share in Volume by Application (2021-2026) Table 55. Global Short-acting Insulin Sales by Application (2021-2026) & (US$ Million) Table 56. Global Short-acting Insulin Sales Market Share in Value by Application (2021-2026) Table 57. Global Short-acting Insulin Price by Application (2021-2026) & (US$/Unit) Table 58. Global Short-acting Insulin Sales by Application (2027-2032) & (K Units) Table 59. Global Short-acting Insulin Sales Market Share in Volume by Application (2027-2032) Table 60. Global Short-acting Insulin Sales by Application (2027-2032) & (US$ Million) Table 61. Global Short-acting Insulin Sales Market Share in Value by Application (2027-2032) Table 62. Global Short-acting Insulin Price by Application (2027-2032) & (US$/Unit) Table 63. North America Short-acting Insulin Sales by Application (2021-2026) & (K Units) Table 64. North America Short-acting Insulin Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Short-acting Insulin Sales by Application (2021-2026) & (K Units) Table 66. Europe Short-acting Insulin Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Short-acting Insulin Sales by Application (2021-2026) & (K Units) Table 68. Asia-Pacific Short-acting Insulin Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Short-acting Insulin Sales by Application (2021-2026) & (K Units) Table 70. Latin America Short-acting Insulin Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Short-acting Insulin Sales by Application (2021-2026) & (K Units) Table 72. Middle East and Africa Short-acting Insulin Sales by Application (2021-2026) & (US$ Million) Table 73. Zhuhai United Pharmaceutical Company Information Table 74. Zhuhai United Pharmaceutical Business Overview Table 75. Zhuhai United Pharmaceutical Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Zhuhai United Pharmaceutical Short-acting Insulin Product Portfolio Table 77. Zhuhai United Pharmaceutical Recent Development Table 78. Wanbang Biopharmaceuticals Company Information Table 79. Wanbang Biopharmaceuticals Business Overview Table 80. Wanbang Biopharmaceuticals Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Wanbang Biopharmaceuticals Short-acting Insulin Product Portfolio Table 82. Wanbang Biopharmaceuticals Recent Development Table 83. Sinovac Biotech Company Information Table 84. Sinovac Biotech Business Overview Table 85. Sinovac Biotech Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Sinovac Biotech Short-acting Insulin Product Portfolio Table 87. Sinovac Biotech Recent Development Table 88. HTBT Company Information Table 89. HTBT Business Overview Table 90. HTBT Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. HTBT Short-acting Insulin Product Portfolio Table 92. HTBT Recent Development Table 93. Tonghua Dongbao Pharmaceutical Company Information Table 94. Tonghua Dongbao Pharmaceutical Business Overview Table 95. Tonghua Dongbao Pharmaceutical Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Tonghua Dongbao Pharmaceutical Short-acting Insulin Product Portfolio Table 97. Tonghua Dongbao Pharmaceutical Recent Development Table 98. Wockhardt Company Information Table 99. Wockhardt Business Overview Table 100. Wockhardt Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Wockhardt Short-acting Insulin Product Portfolio Table 102. Wockhardt Recent Development Table 103. Sanofi Company Information Table 104. Sanofi Business Overview Table 105. Sanofi Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Sanofi Short-acting Insulin Product Portfolio Table 107. Sanofi Recent Development Table 108. Pfizer Company Information Table 109. Pfizer Business Overview Table 110. Pfizer Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Pfizer Short-acting Insulin Product Portfolio Table 112. Pfizer Recent Development Table 113. Novo Nordisk Company Information Table 114. Novo Nordisk Business Overview Table 115. Novo Nordisk Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Novo Nordisk Short-acting Insulin Product Portfolio Table 117. Novo Nordisk Recent Development Table 118. Eli Lilly Company Information Table 119. Eli Lilly Business Overview Table 120. Eli Lilly Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Eli Lilly Short-acting Insulin Product Portfolio Table 122. Eli Lilly Recent Development Table 123. Biocon Biologics Company Information Table 124. Biocon Biologics Business Overview Table 125. Biocon Biologics Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Biocon Biologics Short-acting Insulin Product Portfolio Table 127. Biocon Biologics Recent Development Table 128. Bayer Company Information Table 129. Bayer Business Overview Table 130. Bayer Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Bayer Short-acting Insulin Product Portfolio Table 132. Bayer Recent Development Table 133. BASF Company Information Table 134. BASF Business Overview Table 135. BASF Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. BASF Short-acting Insulin Product Portfolio Table 137. BASF Recent Development Table 138. Abbott Laboratories Company Information Table 139. Abbott Laboratories Business Overview Table 140. Abbott Laboratories Short-acting Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Abbott Laboratories Short-acting Insulin Product Portfolio Table 142. Abbott Laboratories Recent Development Table 143. North America Short-acting Insulin Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 144. North America Short-acting Insulin Sales by Country (2021-2026) & (K Units) Table 145. North America Short-acting Insulin Sales Market Share by Country (2021-2026) Table 146. North America Short-acting Insulin Sales Forecast by Country (2027-2032) & (K Units) Table 147. North America Short-acting Insulin Sales Market Share Forecast by Country (2027-2032) Table 148. North America Short-acting Insulin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. North America Short-acting Insulin Market Size by Country (2021-2026) & (US$ Million) Table 150. North America Short-acting Insulin Market Share by Country (2021-2026) Table 151. North America Short-acting Insulin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. North America Short-acting Insulin Market Share Forecast by Country (2027-2032) Table 153. Europe Short-acting Insulin Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 154. Europe Short-acting Insulin Sales by Country (2021-2026) & (K Units) Table 155. Europe Short-acting Insulin Sales Market Share by Country (2021-2026) Table 156. Europe Short-acting Insulin Sales Forecast by Country (2027-2032) & (K Units) Table 157. Europe Short-acting Insulin Sales Market Share Forecast by Country (2027-2032) Table 158. Europe Short-acting Insulin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Europe Short-acting Insulin Market Size by Country (2021-2026) & (US$ Million) Table 160. Europe Short-acting Insulin Market Share by Country (2021-2026) Table 161. Europe Short-acting Insulin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Europe Short-acting Insulin Market Share Forecast by Country (2027-2032) Table 163. Asia-Pacific Short-acting Insulin Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 164. Asia-Pacific Short-acting Insulin Sales by Country (2021-2026) & (K Units) Table 165. Asia-Pacific Short-acting Insulin Sales Market Share by Country (2021-2026) Table 166. Asia-Pacific Short-acting Insulin Sales Forecast by Country (2027-2032) & (K Units) Table 167. Asia-Pacific Short-acting Insulin Sales Market Share Forecast by Country (2027-2032) Table 168. Asia-Pacific Short-acting Insulin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Asia-Pacific Short-acting Insulin Market Size by Country (2021-2026) & (US$ Million) Table 170. Asia-Pacific Short-acting Insulin Market Share by Country (2021-2026) Table 171. Asia-Pacific Short-acting Insulin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Asia-Pacific Short-acting Insulin Market Share Forecast by Country (2027-2032) Table 173. Latin America Short-acting Insulin Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 174. Latin America Short-acting Insulin Sales by Country (2021-2026) & (K Units) Table 175. Latin America Short-acting Insulin Sales Market Share by Country (2021-2026) Table 176. Latin America Short-acting Insulin Sales Forecast by Country (2027-2032) & (K Units) Table 177. Latin America Short-acting Insulin Sales Market Share Forecast by Country (2027-2032) Table 178. Latin America Short-acting Insulin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 179. Latin America Short-acting Insulin Market Size by Country (2021-2026) & (US$ Million) Table 180. Latin America Short-acting Insulin Market Share by Country (2021-2026) Table 181. Latin America Short-acting Insulin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 182. Latin America Short-acting Insulin Market Share Forecast by Country (2027-2032) Table 183. Middle East and Africa Short-acting Insulin Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 184. Middle East and Africa Short-acting Insulin Sales by Country (2021-2026) & (K Units) Table 185. Middle East and Africa Short-acting Insulin Sales Market Share by Country (2021-2026) Table 186. Middle East and Africa Short-acting Insulin Sales Forecast by Country (2027-2032) & (K Units) Table 187. Middle East and Africa Short-acting Insulin Sales Market Share Forecast by Country (2027-2032) Table 188. Middle East and Africa Short-acting Insulin Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 189. Middle East and Africa Short-acting Insulin Market Size by Country (2021-2026) & (US$ Million) Table 190. Middle East and Africa Short-acting Insulin Market Share by Country (2021-2026) Table 191. Middle East and Africa Short-acting Insulin Market Size Forecast by Country (2027-2032) & (US$ Million) Table 192. Middle East and Africa Short-acting Insulin Market Share Forecast by Country (2027-2032) Table 193. Key Raw Materials Table 194. Raw Materials Key Suppliers Table 195. Short-acting Insulin Distributors List Table 196. Short-acting Insulin Customers List Table 197. Research Programs/Design for This Report Table 198. Authors List of This Report Table 199. Secondary Sources Table 200. Primary Sources List of Figures Figure 1. Short-acting Insulin Image Figure 2. Global Short-acting Insulin Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Short-acting Insulin Market Size (2021-2032) & (US$ Million) Figure 4. Global Short-acting Insulin Sales (2021-2032) & (K Units) Figure 5. Regular Insulin Image Figure 6. Global Regular Insulin Sales YoY Growth (2021-2032) & (K Units) Figure 7. Biosynthetic Human Insulin Image Figure 8. Global Biosynthetic Human Insulin Sales YoY Growth (2021-2032) & (K Units) Figure 9. Recombinant Human Insulin Image Figure 10. Global Recombinant Human Insulin Sales YoY Growth (2021-2032) & (K Units) Figure 11. Other Image Figure 12. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 13. Global Short-acting Insulin Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Short-acting Insulin Market Share by Type 2025 VS 2032 Figure 15. North America Short-acting Insulin Sales Market Share in Volume by Type in 2025 Figure 16. North America Short-acting Insulin Sales Market Share in Value by Type in 2025 Figure 17. Europe Short-acting Insulin Sales Market Share in Volume by Type in 2025 Figure 18. Europe Short-acting Insulin Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Short-acting Insulin Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Short-acting Insulin Sales Market Share in Value by Type in 2025 Figure 21. Latin America Short-acting Insulin Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Short-acting Insulin Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Short-acting Insulin Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Short-acting Insulin Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Short-acting Insulin Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Type 2 Diabetes Image Figure 28. Global Type 2 Diabetes Sales YoY Growth (2021-2032) & (K Units) Figure 29. Type 1 Diabetes Image Figure 30. Global Type 1 Diabetes Sales YoY Growth (2021-2032) & (K Units) Figure 31. Gestational Diabetes Image Figure 32. Global Gestational Diabetes Sales YoY Growth (2021-2032) & (K Units) Figure 33. Complications of Diabetes Image Figure 34. Global Complications of Diabetes Sales YoY Growth (2021-2032) & (K Units) Figure 35. Other Image Figure 36. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 37. Global Short-acting Insulin Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Short-acting Insulin Market Share by Application 2025 VS 2032 Figure 39. North America Short-acting Insulin Sales Market Share in Volume by Application in 2025 Figure 40. North America Short-acting Insulin Sales Market Share in Value by Application in 2025 Figure 41. Europe Short-acting Insulin Sales Market Share in Volume by Application in 2025 Figure 42. Europe Short-acting Insulin Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific Short-acting Insulin Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific Short-acting Insulin Sales Market Share in Value by Application in 2025 Figure 45. Latin America Short-acting Insulin Sales Market Share in Volume by Application in 2025 Figure 46. Latin America Short-acting Insulin Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa Short-acting Insulin Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa Short-acting Insulin Sales Market Share in Value by Application in 2025 Figure 49. North America Short-acting Insulin Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. North America Short-acting Insulin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America Short-acting Insulin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America Short-acting Insulin Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Short-acting Insulin Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Europe Short-acting Insulin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Short-acting Insulin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe Short-acting Insulin Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Short-acting Insulin Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Asia-Pacific Short-acting Insulin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Short-acting Insulin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific Short-acting Insulin Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Short-acting Insulin Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Latin America Short-acting Insulin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Short-acting Insulin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America Short-acting Insulin Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Short-acting Insulin Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 66. Middle East and Africa Short-acting Insulin Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Short-acting Insulin Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa Short-acting Insulin Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Short-acting Insulin Value Chain Figure 70. Key Raw Materials Price Figure 71. Manufacturing Cost Structure Figure 72. Short-acting Insulin Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Regular Insulin
  • Biosynthetic Human Insulin
  • Recombinant Human Insulin
  • Other
Applications
  • Type 2 Diabetes
  • Type 1 Diabetes
  • Gestational Diabetes
  • Complications of Diabetes
  • Other
Companies covered
  • Zhuhai United Pharmaceutical
  • Wanbang Biopharmaceuticals
  • Sinovac Biotech
  • HTBT
  • Tonghua Dongbao Pharmaceutical
  • Wockhardt
  • Sanofi
  • Pfizer
  • Novo Nordisk
  • Eli Lilly
  • Biocon Biologics
  • Bayer
  • BASF
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Short-acting Insulin Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Short-acting Insulin Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Short-acting Insulin Market by Type
  6. 1.3.1 Regular Insulin
  7. 1.3.2 Biosynthetic Human Insulin
  8. 1.3.3 Recombinant Human Insulin
  9. 1.3.4 Other
  10. 1.4 Global Short-acting Insulin Market Size by Type
  11. 1.4.1 Global Short-acting Insulin Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Short-acting Insulin Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Short-acting Insulin Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Short-acting Insulin Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Short-acting Insulin Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Short-acting Insulin Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Short-acting Insulin Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Short-acting Insulin Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Short-acting Insulin Industry Trends
  2. 2.2 Short-acting Insulin Industry Drivers
  3. 2.3 Short-acting Insulin Industry Opportunities and Challenges
  4. 2.4 Short-acting Insulin Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Short-acting Insulin Revenue (2021-2026)
  2. 3.2 Global Top Players by Short-acting Insulin Sales (2021-2026)
  3. 3.3 Global Top Players by Short-acting Insulin Price (2021-2026)
  4. 3.4 Global Short-acting Insulin Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Short-acting Insulin Major Company Production Sites & Headquarters
  6. 3.6 Global Short-acting Insulin Company, Product Type & Application
  7. 3.7 Global Short-acting Insulin Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Short-acting Insulin Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Short-acting Insulin Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Short-acting Insulin Tier 1, Tier 2, and Tier 3
4 Short-acting Insulin Regional Status and Outlook
  1. 4.1 Global Short-acting Insulin Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Short-acting Insulin Historic Market Size by Region
  3. 4.2.1 Global Short-acting Insulin Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Short-acting Insulin Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Short-acting Insulin Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Short-acting Insulin Forecasted Market Size by Region
  7. 4.3.1 Global Short-acting Insulin Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Short-acting Insulin Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Short-acting Insulin Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Short-acting Insulin by Application
  1. 5.1 Short-acting Insulin Market by Application
  2. 5.1.1 Type 2 Diabetes
  3. 5.1.2 Type 1 Diabetes
  4. 5.1.3 Gestational Diabetes
  5. 5.1.4 Complications of Diabetes
  6. 5.1.5 Other
  7. 5.2 Global Short-acting Insulin Market Size by Application
  8. 5.2.1 Global Short-acting Insulin Market Size Overview by Application (2021-2032)
  9. 5.2.2 Global Short-acting Insulin Historic Market Size Review by Application (2021-2026)
  10. 5.2.3 Global Short-acting Insulin Forecasted Market Size by Application (2027-2032)
  11. 5.3 Key Regions Market Size by Application
  12. 5.3.1 North America Short-acting Insulin Sales Breakdown by Application (2021-2026)
  13. 5.3.2 Europe Short-acting Insulin Sales Breakdown by Application (2021-2026)
  14. 5.3.3 Asia-Pacific Short-acting Insulin Sales Breakdown by Application (2021-2026)
  15. 5.3.4 South America Short-acting Insulin Sales Breakdown by Application (2021-2026)
  16. 5.3.5 Middle East and Africa Short-acting Insulin Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Zhuhai United Pharmaceutical
  2. 6.1.1 Zhuhai United Pharmaceutical Company Information
  3. 6.1.2 Zhuhai United Pharmaceutical Business Overview
  4. 6.1.3 Zhuhai United Pharmaceutical Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Zhuhai United Pharmaceutical Short-acting Insulin Product Portfolio
  6. 6.1.5 Zhuhai United Pharmaceutical Recent Developments
  7. 6.2 Wanbang Biopharmaceuticals
  8. 6.2.1 Wanbang Biopharmaceuticals Company Information
  9. 6.2.2 Wanbang Biopharmaceuticals Business Overview
  10. 6.2.3 Wanbang Biopharmaceuticals Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Wanbang Biopharmaceuticals Short-acting Insulin Product Portfolio
  12. 6.2.5 Wanbang Biopharmaceuticals Recent Developments
  13. 6.3 Sinovac Biotech
  14. 6.3.1 Sinovac Biotech Company Information
  15. 6.3.2 Sinovac Biotech Business Overview
  16. 6.3.3 Sinovac Biotech Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Sinovac Biotech Short-acting Insulin Product Portfolio
  18. 6.3.5 Sinovac Biotech Recent Developments
  19. 6.4 HTBT
  20. 6.4.1 HTBT Company Information
  21. 6.4.2 HTBT Business Overview
  22. 6.4.3 HTBT Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 HTBT Short-acting Insulin Product Portfolio
  24. 6.4.5 HTBT Recent Developments
  25. 6.5 Tonghua Dongbao Pharmaceutical
  26. 6.5.1 Tonghua Dongbao Pharmaceutical Company Information
  27. 6.5.2 Tonghua Dongbao Pharmaceutical Business Overview
  28. 6.5.3 Tonghua Dongbao Pharmaceutical Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Tonghua Dongbao Pharmaceutical Short-acting Insulin Product Portfolio
  30. 6.5.5 Tonghua Dongbao Pharmaceutical Recent Developments
  31. 6.6 Wockhardt
  32. 6.6.1 Wockhardt Company Information
  33. 6.6.2 Wockhardt Business Overview
  34. 6.6.3 Wockhardt Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Wockhardt Short-acting Insulin Product Portfolio
  36. 6.6.5 Wockhardt Recent Developments
  37. 6.7 Sanofi
  38. 6.7.1 Sanofi Company Information
  39. 6.7.2 Sanofi Business Overview
  40. 6.7.3 Sanofi Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Sanofi Short-acting Insulin Product Portfolio
  42. 6.7.5 Sanofi Recent Developments
  43. 6.8 Pfizer
  44. 6.8.1 Pfizer Company Information
  45. 6.8.2 Pfizer Business Overview
  46. 6.8.3 Pfizer Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Pfizer Short-acting Insulin Product Portfolio
  48. 6.8.5 Pfizer Recent Developments
  49. 6.9 Novo Nordisk
  50. 6.9.1 Novo Nordisk Company Information
  51. 6.9.2 Novo Nordisk Business Overview
  52. 6.9.3 Novo Nordisk Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Novo Nordisk Short-acting Insulin Product Portfolio
  54. 6.9.5 Novo Nordisk Recent Developments
  55. 6.10 Eli Lilly
  56. 6.10.1 Eli Lilly Company Information
  57. 6.10.2 Eli Lilly Business Overview
  58. 6.10.3 Eli Lilly Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Eli Lilly Short-acting Insulin Product Portfolio
  60. 6.10.5 Eli Lilly Recent Developments
  61. 6.11 Biocon Biologics
  62. 6.11.1 Biocon Biologics Company Information
  63. 6.11.2 Biocon Biologics Business Overview
  64. 6.11.3 Biocon Biologics Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Biocon Biologics Short-acting Insulin Product Portfolio
  66. 6.11.5 Biocon Biologics Recent Developments
  67. 6.12 Bayer
  68. 6.12.1 Bayer Company Information
  69. 6.12.2 Bayer Business Overview
  70. 6.12.3 Bayer Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Bayer Short-acting Insulin Product Portfolio
  72. 6.12.5 Bayer Recent Developments
  73. 6.13 BASF
  74. 6.13.1 BASF Company Information
  75. 6.13.2 BASF Business Overview
  76. 6.13.3 BASF Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 BASF Short-acting Insulin Product Portfolio
  78. 6.13.5 BASF Recent Developments
  79. 6.14 Abbott Laboratories
  80. 6.14.1 Abbott Laboratories Company Information
  81. 6.14.2 Abbott Laboratories Business Overview
  82. 6.14.3 Abbott Laboratories Short-acting Insulin Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Abbott Laboratories Short-acting Insulin Product Portfolio
  84. 6.14.5 Abbott Laboratories Recent Developments
7 North America by Country
  1. 7.1 North America Short-acting Insulin Sales by Country
  2. 7.1.1 North America Short-acting Insulin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Short-acting Insulin Sales by Country (2021-2026)
  4. 7.1.3 North America Short-acting Insulin Sales Forecast by Country (2027-2032)
  5. 7.2 North America Short-acting Insulin Market Size by Country
  6. 7.2.1 North America Short-acting Insulin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Short-acting Insulin Market Size by Country (2021-2026)
  8. 7.2.3 North America Short-acting Insulin Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Short-acting Insulin Sales by Country
  2. 8.1.1 Europe Short-acting Insulin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Short-acting Insulin Sales by Country (2021-2026)
  4. 8.1.3 Europe Short-acting Insulin Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Short-acting Insulin Market Size by Country
  6. 8.2.1 Europe Short-acting Insulin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Short-acting Insulin Market Size by Country (2021-2026)
  8. 8.2.3 Europe Short-acting Insulin Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Short-acting Insulin Sales by Country
  2. 9.1.1 Asia-Pacific Short-acting Insulin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Short-acting Insulin Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Short-acting Insulin Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Short-acting Insulin Market Size by Country
  6. 9.2.1 Asia-Pacific Short-acting Insulin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Short-acting Insulin Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Short-acting Insulin Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Short-acting Insulin Sales by Country
  2. 10.1.1 South America Short-acting Insulin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Short-acting Insulin Sales by Country (2021-2026)
  4. 10.1.3 South America Short-acting Insulin Sales Forecast by Country (2027-2032)
  5. 10.2 South America Short-acting Insulin Market Size by Country
  6. 10.2.1 South America Short-acting Insulin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Short-acting Insulin Market Size by Country (2021-2026)
  8. 10.2.3 South America Short-acting Insulin Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Short-acting Insulin Sales by Country
  2. 11.1.1 Middle East and Africa Short-acting Insulin Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Short-acting Insulin Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Short-acting Insulin Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Short-acting Insulin Market Size by Country
  6. 11.2.1 Middle East and Africa Short-acting Insulin Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Short-acting Insulin Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Short-acting Insulin Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Short-acting Insulin Value Chain Analysis
  2. 12.1.1 Short-acting Insulin Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Short-acting Insulin Production Mode & Process
  7. 12.2 Short-acting Insulin Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Short-acting Insulin Distributors
  10. 12.2.3 Short-acting Insulin Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst